Key statistics
As of last trade, Addex Therapeutics Ltd (APE1:DUS) traded at 6.10, 11.93% above the 52 week low of 5.45 set on Feb 13, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 6.10 |
|---|---|
| High | 6.10 |
| Low | 6.10 |
| Bid | 6.10 |
| Offer | 6.65 |
| Previous close | 5.45 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 1.82m |
| Free float | 1.61m |
| P/E (TTM) | -- |
| Market cap | 14.13m USD |
| EPS (TTM) | -8.84 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 08:31 GMT.
More ▼
Announcements
- Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment
- Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
- Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
- Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
- Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025
- Addex Increases Issued Share Capital to Create Treasury Shares
- Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
- Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
- Addex Appoints Bank of New York Mellon as Depositary Bank
- Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
More ▼
